Discovery of a First-in-Class Potent Small Molecule Antagonist against the Adrenomedullin-2 Receptor-Reference-Cited by-同舟云学术

Discovery of a First-in-Class Potent Small Molecule Antagonist against the Adrenomedullin-2 Receptor

Published:2020-06-25 Issue:4 Volume:3 Page:706-719
ISSN:2575-9108
Container-title:ACS Pharmacology & Translational Science
language:en
Short-container-title:ACS Pharmacol. Transl. Sci.

Author:

Avgoustou Paris¹^ORCID,Jailani Ameera B. A.¹^ORCID,Zirimwabagabo Jean-Olivier²^ORCID,Tozer Matthew J.³^ORCID,Gibson Karl R.⁴^ORCID,Glossop Paul A.⁴^ORCID,Mills James E. J.⁴^ORCID,Porter Roderick A.⁵^ORCID,Blaney Paul⁶^ORCID,Bungay Peter J.⁷^ORCID,Wang Ning¹^ORCID,Shaw Alice P.¹^ORCID,Bigos Kamilla J. A.¹^ORCID,Holmes Joseph L.¹^ORCID,Warrington Jessica I.¹^ORCID,Skerry Timothy M.¹^ORCID,Harrity Joseph P. A.²^ORCID,Richards Gareth O.¹^ORCID

Affiliation:

1. Department of Oncology and Metabolism, University of Sheffield, Sheffield, S10 2TN, U.K.

2. Department of Chemistry, University of Sheffield, Sheffield, S10 2TN, U.K.

3. Matt Tozer Consultancy, Bognor Regis, PO21 1DY, U.K.

4. Sandexis Medicinal Chemistry Ltd, Sandwich, Kent CT13 9ND, U.K.

5. Rod Porter Consultancy, Ashwell, Hertfordshire SG7 5PG, U.K.

6. Concept Life Sciences, High Peak, SK23 0PG, U.K.

7. Sympetrus Ltd., Bishop’s Stortford, Hertfordshire CM23 3BT, U.K.

Funder

Prostate Cancer UK

University of Sheffield

Wellcome Trust